Results 171 to 180 of about 71,654 (304)

The Differing Phenotypes of the Three Most Common Postsynaptic Congenital Myasthenic Syndromes Governed by Their Underlying Molecular Pathogenic Mechanisms

Muscle &Nerve, EarlyView.
ABSTRACT The congenital myasthenic syndromes are rare disorders of impaired signal transmission at the neuromuscular junction. Despite next generation sequencing facilitating the identification of variants in myasthenic‐associated genes, these variants are frequently of unknown significance and the clinical diagnosis can be delayed.
David Beeson
wiley   +1 more source

Machine learning discovers numerous new computational principles supporting elementary motion detection. [PDF]

Nat Commun
Poleg-Polsky A.
europepmc   +1 more source

Clinical Characteristics and Treatment Management of Seronegative Myasthenia Gravis: A Systematic Review of the Literature

Muscle &Nerve, EarlyView.
ABSTRACT Seronegative myasthenia gravis (SNMG) is characterized by the absence of detectable autoantibodies against known MG targets, despite clinical and electrophysiological evidence of a postsynaptic neuromuscular junction disorder. The aim of this systematic review was to better define clinical features, diagnostic clues and treatment outcome of ...
Massimiliano Ugo Verza, Mattia Schiavolin, Francesca Beretta, Sara Cornacchini, Antonio Lotti, Gregorio Spagni, Valentina Damato   +6 more
wiley   +1 more source

Mechanistic explanation of neuroplasticity using equivalent circuits. [PDF]

Front Comput Neurosci
Nilsson MNP.
europepmc   +1 more source

Optimization of the Cell‐Based Assay Methodology to Study Degradation of Acetylcholine Receptors (Antigenic Modulation) by Antibodies From Myasthenia Gravis Patients

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Degradation of cell‐surface acetylcholine receptors (AChRs) by antigenic modulation is a key pathogenic mechanism of myasthenia gravis (MG) autoantibodies, yet standard assays primarily detect antibody binding rather than functional effects.
Peng Du, Marina Mané‐Damas, Fien M. Verhamme, Mahan Moshir, Peter Ulrichts, Barbie Machiels, Mario Losen, Pilar Martinez‐Martinez   +7 more
wiley   +1 more source

Differential selectivity of microglia and astrocytes in HIV-1 gp120-induced synaptic pruning. [PDF]

Brain
Watson ZT, Valdebenito-Silva S, Spurgat M, Ru W, Zheng J, Maurelli MK, Liang Y, Yuan S, Eugenin E, Tang SJ.   +9 more
europepmc   +1 more source

Graded traumatic brain injury severity differentially modulates microglial and astrocytic polarization states and response to minocycline

Neuroprotection, EarlyView.
Schematic diagram of the experimental design and key findings of traumatic brain injury (TBI) with varying severities. Mild, moderate, and severe TBI were induced in the right motor cortex of mice using the controlled cortical impact (CCI) method, with impact depths of 0.5, 1.0, and 2.0 mm, respectively. A subset of severe TBI mice received minocycline
Yan Yu, Chen Wang, Jinyu Zhu, Jiahui Du, Hao Li, Shuyi Ning, Rui Yang, Yiwen Ma, Mengyuan Yuan, Wei Shen, Huailin Wang, Huihui Jiang, Liping Chen, Haitao Wu   +13 more
wiley   +1 more source

APP family in inhibitory neurons controls inhibitory recruitment and short-term plasticity in the hippocampus. [PDF]

Mol Brain
Lee SH, Kang J, Zhang C, Bolshakov VY, Shen J.   +4 more
europepmc   +1 more source

Investigation of the Mechanism of Cinnamaldehyde in Irritable Bowel Syndrome Based via Network Pharmacology, Molecular Docking, and Animal Experiments

Pediatric Discovery, EarlyView.
Through network pharmacology and molecular docking, it has been discovered that CA can target MAOB, among other proteins, to exert a therapeutic effect in IBS. In vivo, CA lowered visceral hypersensitivity, anxiety and depression‐like behaviors, and fecal water content, highlighting its therapeutic potential for IBS via anti‐inflammatory pathways ...
Qingyang Yu, Boqing Xu, Chunfang Dai, Yayan Pang, Zhifang Dong   +4 more
wiley   +1 more source

GABA_A Receptor Modulators as Emerging Therapeutic Agents for Depressive Disorders. [PDF]

Drug Des Devel Ther
Guan BY, Li Y.
europepmc   +1 more source